Andere talen Kiromic BioPharma, Inc.

Aandelen

KRBP

US4976342042

Vertraagde tijd OTC Markets Andere beurzen 19:56:26 16-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
3,08 ^USD	+11,59%		+27,80%	+254,02%

10/05	Kiromic BioPharma, Inc. Rapporteert de winstresultaten voor het eerste kwartaal dat eindigde op 31 maart 2024	CI
24/04	Kiromic BioPharma, Inc. Rapporteert consistente gunstige veiligheid, verdraagbaarheid en werkzaamheid bij de eerste drie patiënten van de Deltacel-01 klinische studie	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Kiromic BioPharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05
Kiromic BioPharma, Inc. announced that it has received $2 million in funding	01/05
Kiromic BioPharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients	24/04
Kiromic BioPharma, Inc. Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients	24/04
Kiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial	02/04
Kiromic Biopharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial	02/04
Kiromic BioPharma, Inc. announced that it has received $2 million in funding	02/04
EARLY EFFICACY RESULTS SHOW PRIMARY LUNG TUMOR STABILIZATION AND COMPLETE DISAPPEARANCE OF BRAIN METASTASES IN SECOND PATIENT IN KIROMIC BIOPHARMA'S DELTACEL-01 CLINICAL TRIAL	20/03
Early Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial	19/03
Kiromic BioPharma, Inc. Reports Early Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Deltacel-01 Clinical Trial	19/03
Kiromic BioPharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	19/03
Kiromic BioPharma : Corporate Presentation	06/03
KIROMIC BIOPHARMA ADDS VIRGINIA ONCOLOGY ASSOCIATES, PC AS THE SECOND CLINICAL TRIAL SITE IN THE ONGOING PHASE 1 DELTACEL-01 TRIAL	04/03
Kiromic BioPharma Adds Virginia Oncology Associates, PC as the Second Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 Trial	01/03
Kiromic BioPharma to Present at the OTC Markets’ Virtual Life Science Investor Forum on March 7th	29/02
Kiromic BioPharma to Present at the OTC Markets’ Virtual Life Science Investor Forum on March 7th	28/02
RESULTS FROM FIRST PATIENT IN KIROMIC BIOPHARMA'S DELTACEL-01 CLINICAL TRIAL INDICATE TUMOR REDUCTION AT TWO MONTHS	15/02
Results from First Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial Indicate Tumor Reduction at Two Months	14/02
Kiromic BioPharma, Inc. Announces Results from First Patient in Kiromic BioPharma's Deltacel-01 Clinical Trial Indicate Tumor Reduction at Two Months	14/02
Kiromic BioPharma, Inc. announced that it has received $2 million in funding	12/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Kiromic BioPharma, Inc.

Aandelen

KRBP

US4976342042

Andere talen

Filters